

Литература к разделу:

ЦИТОКИНЫ В СИСТЕМЕ ИММУНИТЕТА

Литература к подразделу 1

1. Тотолян А.А., Фрейдлин И.С. Клетки иммунной системы. – Т. 1–2. – СПб., «Наука», 2000. – 231 с.
2. Фрейдлин И.С., Тотолян А.А. Клетки иммунной системы. – Т. 3–5. – СПб., «Наука», 2001. – 392 с.
3. Симбирцев А.С. // Цитокины и воспаление. – 2002. – Т. 1, №1. – С. 9–16.
4. Aggarwal B., Vilcek J. Tumor Necrosis Factor: Structure, Function and Mechanism of Action. – Marcel Dekker, 1992. – P. 1–624.
5. Aggarwal B.B., Pocsic E. // Arch. Biochem. Biophysics. – 1992. – Vol. 292, №2. – P. 335–359.
6. Симбирцев А.С. // Иммунология. – 1998. – №6. – С. 3–8.
7. Arend W.P., Malyak M., Guthridge C.J., Gabay C. // Ann. Rev. Immunol. – 1998. – Vol. 16. – P. 27–55.
8. Austgulen R., Johnsen H., Kjollesdal A.M., et al. // Obstet. Gynecol. – 1993. – Vol. 82, №3. – P. 343–347.
9. Austgulen R., Liabakk N.B., Espevik T. // Tidsskr. Nor. Laegeforen. – 1992. – Vol. 112, №28. – P. 3545–3547.
10. Austgulen R., Liabakk N.B., Lien E., Espevik T. // Pediatr. Res. – 1993. – Vol. 33, №1. – P. 82–87.
11. Bry K., Lappalainen U., Waffarn F. et al. // Pediatr. Res. – 1994. – Vol. 35, №1. – P. 130–134.
12. Chao C.C., Hu S., Sheng W.S. et al. // Clin. Immunol. Immunopathol. – 1995. – Vol. 77, №3. P. 358–365.
13. De Beaux A., Maingay J., Ross J.A. et al. // J. Interferon Cytokine Res. – 1995. – Vol. 15. – P. 441–445.
14. Tilg H., Vannier E., Vachino G. et al. // J. Exp. Med. – 1993. – Vol. 178, №5. – P. 1629–1636.
15. Симбирцев А.С. // Мед. иммунология. – 1999. – Т. 1, №3–4. – С. 133–134.
16. Анциферова М.А., Казаков А.А., Александров Г.А. // Цитокины и воспаление. – 2002. – Т. 1, №2. – С. 65.
17. Ботвиньева В.В., Геворкян А.К., Бегляров Р.О. // 5-й Конгресс педиатров России. – М., 1999. – С. 43.
18. Долгов В.В., Щетникович К.А., Лукичева Т.И., Прудник И.М. Методические аспекты определения индивидуальных белков. Учебно-методическое пособие. – М., 1998. – 88 с.
19. Кетлинский С.А., Калинина Н.М. // Иммунология. – 1995. – №3. – С. 30–44.
20. Котов А.Ю. Разработка диагностических тестсистем и их использование для изучения продукции провоспалительных цитокинов при воспалительных процессах: Автореф. дисс. ... канд. мед. наук. – СПб., 1999. – 20 с.
21. Лимфоциты. Методы. / Под ред. Дж.Клауса: Пер. с англ. – М.: Мир, 1990. – 395 с.
22. Назаров П.Г. Реактанты острой фазы воспаления. – С-Пб., «Наука», 2001. – 424 с.
23. Castell J.V., Gomez-Lechon M.J., David M. et al. // Hepatology. – 1990. – Vol. 12. – P. 1179–1186.
24. Gallin J.I. et al. Inflammation: Basic Principles and Clinical Correlates. – 2nd ed. – Raven Press, 1992.
25. Low P.S., Lee B.W., Yap H.K. et al. // Ann. Trop. Paediatr. – 1995. – Vol. 115, №1. – P. 55–59.

26. Mathiesen T., Edner G., Ulfarsson E., Andersson B. // J. Neurosurg. – 1997. – Vol. 87, №2. – P. 215–220.
27. Moshage H. // J. Pathol. – 1997. – Vol. 181, №3. – P. 257–266.
28. Петров Р.В. Иммунология. – М.: Медицина, 1987. – 368 с.
29. Петров Р.В., Лопухин Ю.М., Чередеев А.Н. и др. Оценка иммунного статуса человека. Методические рекомендации. – М.: Медицина, 1994.
30. Ройт А., Бростофф Дж., Мейл Д. Иммунология: Пер. с англ. – М., «Мир», 2000. – С. 168–334.
31. Симбирцев А.С. Биология интерлейкина1 человека в норме и при патологии Автореф. дисс. ... докт. мед. наук. – СПб., 1993. – 47 с.
32. Соколова Н.Г., Конусова В.Г., Пигарева Н.В. и др. // Мед. иммунология. – 1999. – Т. 1, №3–4. – С. 136.
33. Wigmore S.J., Fearon K.C., Maingay J.P. et al. // Am. J. Physiol. – 1997. – Vol. 273, №4. – P. 720–726.
34. Bessler H., Straussberg R., Gurary N. et al. // Arch. Dis. Child. – 1996. – Vol. 75. – P. 197–201.
35. Bessler H., Mendel C., Straussberg R. et al. // Biology of the Neonate. – 1999. – Vol. 75, №4. – P. 225–233.
36. Kavelaars A., Zijlstra J., Bakker J.M. et al. // Eur. J. Immunol. – 1995. – Vol. 25. – P. 1346–51.
37. Sun Q., Burton R.L., Pollok K.E. et al. // Cell. Immunol. – 1999. – Vol. 195, №2. – P. 81–88.
38. Viganò A., Esposito S., Arienti D. et al. // Biol. Neonate. – 1999. – Vol. 75, №1. – P. 1–8
39. Шаимова В.А. Роль провоспалительных цитокинов при заболеваниях глаз // Цитокины и Воспаление.- 2005.- Т. 4.- № 2.- С. 13-16.
40. Eskdale J., Kube D., Tesch H., Gallagher G. Mapping of the human IL10 gene and further characterization of the 5' flanking sequence // Immunogenetics : journal. - 1997. - Vol. 46, no. 2. - P. 120-128.
41. Mosser D. M., Zhang X. Interleukin-10: new perspectives on an old cytokine // Immunological Reviews : journal. - 2008. - December (vol. 226, no.1). - P. 205-218.
42. Asadullah K., Sterry W., Volk H.D. Interleukin-10 therapy-review of a new approach // Pharmacol. Rev.- 2003.- V. 55.- № 2.- P. 241-269.
43. Moore K.W., de Waal M.R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor // Annu Rev. Immunol.- 2001.- V. 19.- P. 683-765.
44. Reich K., Garbe C., Blaschke V. et al. Response of psoriasis to Interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation // J Invest. Dermatol.- 2001.- V. 116.- P. 319-329.
45. Кадагидзе З.Г. Цитокины // Практическая онкология. – 2003. – Т. 4. – № 3. – С. 131-139
46. Александрова Ю.Н. О системе цитокинов. // Педиатрия. – 2007. – Том 86. – №3. – С.124-128

Литература к [подразделу 4](#)

1. Deverman BE, Patterson PH (2009) Cytokines and CNS Development. Neuron 64(1): 61-78.
2. Zídek Z, Anzenbacher P, Kmonickoval E (2009) Current status and challenges of cytokine pharmacology. Br J Pharmacol 157(3): 342- 361.
3. Barnes PJ (2008) The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 118(11): 3546-3556.
4. Owen JA, Punt J, Stranford SA (2013) Kuby Immunology. WH Freeman & Company, New York, USA.

5. Dinarello CA (2007) Historical Review of Cytokines. *Eur J Immunol* 37(Suppl 1): S34-S45.
6. Wilson CJ, Finch CE, Cohen HJ (2002) Cytokines and cognition-the case for a head-to-toe inflammatory paradigm. *J Am Geriatr Soc* 50(12): 2041-2056.
7. Kips JC (2001) Cytokines in asthma. *Eur Respir J* 18(34): 24s-33s.
8. Steinke JW, Borish L (2001) Th2 cytokines and asthma Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. *Respir Res* 2(2): 66-70.
9. Chung F (2001) Antiinflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12, interferon γ . *Mediators Inflamm* 10(2): 51-59.
10. Mahajan S, Mehta AA (2006) Role of cytokines in pathophysiology of asthma. *Iran J Pharmacol Therap* 5: 1-14.
11. Kedzierska K, Crowe SM (2001) Cytokines and HIV-1: Interactions and clinical implications. *Antivir Chem Chemother* 12(3): 133-150.
12. Fox DA (1997) The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. *Arthritis Rheum* 40(4): 598-609.
13. Thomas R, Lipsky PE (1997) Could endogenous self-peptides presented by dendritic cells initiate rheumatoid arthritis? *Immunol Today* 17(12): 559-564.
14. Mojcik CF, Shevach EM (1997) Adhesion molecules: a rheumatologic perspective. *Arthritis Rheum* 40(6): 991-1004.
15. Kunkel SL, Lukacs N, Kasama T, Streiter RM (1996) The role of chemokines in inflammatory joint disease. *J Leukoc Biol* 59(1): 6-12.
16. Vitkovic L, Boackaert J, Jacque C (2000) Inflammatory cytokines: neuromodulators in normal brain? *J Neurochem* 74(2): 457-471.
17. Sheng JG, Mrak RE, Griffin WS (1998) Enlarged and phagocytic, but not primed, interleukin-1 alpha-immunoreactive microglia increase with age in normal human brain. *Acta Neuropathol* 95(3): 229-234.
18. Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, et al. (2002) Control of synaptic strength by glial TNF alpha. *Science* 295(5563): 2282-2285.
19. Cingolani LA, Thalhammer A, Yu LM, Catalano M, Ramos T, et al. (2008) Activity-dependent regulation of synaptic AMPA receptor composition and abundance by beta3 integrins. *Neuron* 58(5): 749- 762.
20. Steinman L (2008) Nuanced role of cytokines in three major human brain disorders. *J Clin Invest* 118(11): 3557-3563.
21. Sivakumar P, Das AM (2008) Fibrosis, chronic inflammation and new pathways for drug discovery. *Inflamm Res* 57(9): 410-418.
22. Varga J (2008) Systemic sclerosis: an update. *Bull NYU Hosp Jt Dis* 66(3): 198-202.
23. Nograles KE, Brasington RD, Bowcock AM (2009) New insights into the pathogenesis and genetics of psoriatic arthritis. *Nat Clin Pract Rheumatol* 5(2): 83-91.
24. Urra X, Cervera A, Obach V, Climent N, Planas AM, Chamorro A (2009) Monocytes are major players in the prognosis and risk of infection after acute stroke. *Stroke* 40(4): 1262-1268.
25. Xing HQ, Hayakawa H, Izumo K, Kubota R, Gelpi E, et al. (2009) *In vivo* expression of proinflammatory cytokines in HIV encephalitis: an analysis of 11 autopsy cases. *Neuropathology* 29(4): 433-442.
26. Hao Q, Wang L, Tang H (2009) Vascular endothelial growth factor induces protein kinase D dependent production of pro-inflammatory cytokines in endothelial cells. *Am J Physiol Cell Physiol* 296(4): 821-827.
27. Sengupta SR, Das NK, Datta PK (2008) Pathogenesis, clinical features and pathology of chronic arsenicosis. *Indian J Dermatol Venereol Leprol* 74(6): 559-570.
28. Curtin NM, Mills KH, Connor TJ (2009) Psychological stress increases expression of IL-10 and its homolog IL-19 via beta adrenoceptor activation: Reversal by the anxiolytic chlordiazepoxide. *Brain Behav Immun* 23(3): 371-379.

29. Feldmann M (2008) Many cytokines are very useful therapeutic targets in disease. *J Clin Invest* 118(11): 3533-3536.
30. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, et al. (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. *Arthritis Rheum* 36(12): 1681-1690.
31. Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned. *Annu Rev Immunol* 19: 163-196.
32. Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, et al. (2004) Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')₂ fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. *Crit Care Med* 32(11): 2173-2182.
33. Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, et al. (2008) The role of a soluble TNF α receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. *Thorax* 63(7): 584-591.
34. Lipsky PE (2006) Interleukin-6 and rheumatic diseases. *Arthritis Res Ther* (Suppl 2): S4.
35. Hudis CA (2007) Trastuzumab- Mechanism of Action and Use in Clinical Practice. *N Engl J Med* 357(1): 39-51.
36. Hudziak, RM, Lewis GD, Winget M, Fendly BM, Shepard HM, et al. (1989) p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. *Mol Cell Biol* 9(3): 1165-1172.
37. Hubel K, Dale DC, Liles WC (2002) Therapeutic Use of Cytokines to Modulate Phagocyte Function for the Treatment of Infectious Diseases: Current Status of Granulocyte Colony-Stimulating Factor, Granulocyte-Macrophage Colony-Stimulating Factor, Macrophage Colony-Stimulating Factor, and Interferon- γ . *J Infect Dis* 185(10): 1490-1501.
38. Gallin JL, Farber JM, Holland SM, Nutman TB (1995) Interferon-gamma in the management of infectious diseases. *Ann Intern Med* 123(3): 216-224.
39. Murray HW (1994) Interferon-gamma and host antimicrobial defense: current and future clinical applications. *Am J Med* 97(5): 459-467.
40. Holland SM, Eisenstein E, Kuhns DB, Turner ML, Fleisher TA, et al. (1994) Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. *N Engl J Med* 330(19): 1348-55.
41. Badaro R, Falcoff E, Badaro FS, Carvalho EM, Pedral-Sampaio D, et al. (1990) Treatment of visceral leishmaniasis with pentavalent antimony and interferon-gamma. *N Engl J Med* 322(1): 16-21.
42. Condos R, Rom WN, Schluger NW (1997) Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. *Lancet* 349(9064): 1513-1515.
43. Hendeles L, Asmus M, Chesrown S (2004) Evaluation of cytokine modulators for asthma. *Paediatr Respir Rev* 5 (Suppl A): S107-S112.
44. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, et al. (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. *Lancet* 356(9248): 2144-2148.
45. Vugmeyster Y, Szklut P, Tchistiakova L, Abraham W, Kasaian M, et al. (2008) Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms. *Int Immunopharmacol* 8(3): 477-483.
46. Lee S, Margolin K (2011) Cytokines in cancer immunotherapy. *Cancers* 3(4): 3856-3893.
47. Kontermann RE (2011) Strategies for extended serum half-life of protein therapeutics. *Curr Opin Biotechnol* 22(6): 868-876.
48. Boyman O, Surh CD, Sprent J (2006) Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. *Expert Opin Biol Ther* 6(12): 1323-1331.

49. Brown AS, Hooton J, Schaefer CA, Zhang H, Petkova E, et al. (2004) Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. *Am J Psychiatry* 161(5): 889-895.
50. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Wagner RL, et al. (2001) Maternal cytokine levels during pregnancy and adult psychosis. *Brain Behav Immun* 15(4): 411-420.
51. Anderlini P, Przepiorka D, Seong D, Miller P, Sundberg J, et al. (1996) Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. *Transfusion* 36(7): 590-595.
52. Price TH, Bowden RA, Boeckh M, Bux J, Nelson K, et al. (2000) Phase 18. I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. *Blood* 95(11): 3302-3309.
53. Freedman MH (1997) Safety and long-term administration of granulocyte colony-stimulating factor for severe chronic neutropenia. *Curr Opin Hematol* 4(3): 217-224.
54. Stroncek DF, Yau YY, Oblitas J, Leitman SF (2001) Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone. *Transfusion* 41(8): 1037-1044.
55. Katoh M, Takada M, Nakayama M, Umeda M (1996) Pulmonary toxicity during granulocyte colony-stimulating factor administration and neutrophils. *Chest* 110: 576-587.
56. Niitsu N, Iki S, Muroi K, Motomura S, Murakami M, et al. (1997) Interstitial pneumonia in patients receiving granulocyte colony-stimulating factor during chemotherapy: survey in Japan 1991-96. *Br J Cancer* 76(12): 1661-1666.
57. Hilbe W, Nussbaumer W, Bonatti H, Thaler J, Niederwieser D, et al. (2000) Unusual adverse events following peripheral blood stem cell (PBSC) mobilisation using granulocyte colony stimulating factor (G-CSF) in healthy donors. *Bone Marrow Transplant* 26: 811-823.
58. Peters WP, Shogan JS, Shpall EJ, Jones RB, Kim CS (1988) Recombinant human granulocyte-macrophage colony-stimulating factor produces fever. *Lancet* 1(8591): 950.
59. Lieschke GJ, Cebon J, Morstyn G (1989) Characterization of the clinical effects after the first dose of bacterially synthesized recombinant granulocyte macrophage colony-stimulating factor. *Blood* 74: 2634-2643.
60. Arnig M, Kliche KO, Schneider W (1991) GM-CSF therapy and capillary-leak syndrome. *Ann Hematol* 62(2-3): 83.
61. Jonasch E, Haluska FG (2001) Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities. *Oncologist* 6(1): 34-55.
62. Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, et al. (2000) Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. *Cancer J* 6(3): 139-145.
63. Greenberg DB, Jonasch E, Gadd MA, Ryan BF, Everett JR, et al. (2000) Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. *Cancer* 89(2): 356-362.
64. Jones TH, Wadler S, Hupart KH (1998) Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha. *Semin Oncol* 25 (1 Suppl 1): 54-63.
65. Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, et al. (2006) Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. *Gut* 55(8): 1131-1137.